AbbVie Inc. (BVMF:ABBV34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 1.91T -2.7% |
| Revenue (ttm) | 327.71B +9.5% |
| Net Income | 18.75B -13.3% |
| EPS | 10.59 -13.2% |
| Shares Out | n/a |
| PE Ratio | 101.85 |
| Forward PE | 14.28 |
| Dividend | 1.43 (2.13%) |
| Ex-Dividend Date | Apr 14, 2026 |
| Volume | n/a |
| Average Volume | 3,934 |
| Open | 68.11 |
| Previous Close | 66.00 |
| Day's Range | 66.39 - 68.11 |
| 52-Week Range | 58.81 - 81.36 |
| Beta | 0.31 |
| RSI | 51.73 |
| Earnings Date | Apr 29, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial numbers in USD Financial StatementsNews
AbbVie price target lowered to $235 from $236 at Evercore ISI
Evercore ISI lowered the firm’s price target on AbbVie (ABBV) to $235 from $236 and keeps an Outperform rating on the shares.
3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26
The article uses TipRanks’ Dividend Aristocrat tool to identify AbbVie ($ABBV), Abbott Laboratories ($ABT), and NextEra Energy ($NEE) as three dividend aristocrat stocks with a Strong Buy rating on Wa...
AbbVie price target raised to $298 from $294 at Piper Sandler
Piper Sandler raised the firm’s price target on AbbVie (ABBV) to $298 from $294 and keeps an Overweight rating on the shares. The depth of AbbVie’s inflammatory bowel disease pipeline…
AbbVie Transcript: Bank of America Global Healthcare Conference 2026
Management projects strong revenue and margin growth through 2031, driven by core products, diversified pipeline, and strategic M&A. Key innovations include new obesity assets, combination therapies in IBD, and advances in CAR T and psychedelics.
AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting
AbbVie NYSE: ABBV told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its dr...
AbbVie Transcript: AGM 2026
Record revenues and strong sales growth fueled increased R&D and strategic investments. Shareholders approved director elections, auditor ratification, and executive compensation, but rejected proposals to eliminate supermajority voting and require an independent board chair.
AbbVie to Present at the Bank of America Securities Healthcare Conference
NORTH CHICAGO, Ill., May 6, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 13, 2026.
AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW
AbbVie (ABBV) announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week, or DDW, Annual Meeting, May 2-5 in Chicago. AbbVie will present 18…
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
AbbVie presents 18 abstracts in Crohn's disease and ulcerative colitis Breadth of data from real-world evidence and clinical trials reinforce risankizumab and upadacitinib efficacy, safety profile, an...
AbbVie price target raised to $236 from $232 at Evercore ISI
Evercore ISI raised the firm’s price target on AbbVie (ABBV) to $236 from $232 and keeps an Outperform rating on the shares.
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat
Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely need...
AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried
AbbVie delivered a strong earnings beat this week, driven by its immunology portfolio. WSJ's David Wainer explains why Wall Street is still jittery.
Big Pharma M&A set for mega year as patent expiries drive deal urgency
Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV), jointly with adMare BioInnovations, today recognized RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award, a priz...
AbbVie price target raised to $278 from $270 at Morgan Stanley
Morgan Stanley raised the firm’s price target on AbbVie (ABBV) to $278 from $270 and keeps an Overweight rating on the shares. The company reported a solid quarter from the…
AbbVie price target raised to $265 from $262 at Canaccord
Canaccord analyst Gary Nachman raised the firm’s price target on AbbVie (ABBV) to $265 from $262 and keeps a Buy rating on the shares. The firm said ABBV delivered upside…
Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month
Through its loyalty rewards program Allē, Allergan Aesthetics will donate to The Skin Cancer Foundation $10 for every new member who joins from a referral in May, up to $100,000. IRVINE, Calif.
AbbVie upgraded to Buy at BofA on durable growth
As previously reported, BofA analyst Tim Anderson upgraded AbbVie (ABBV) to Buy from Neutral with a price target of $234, up from $226. The firm believes concerns around competitive erosion…
AbbVie upgraded to Buy from Neutral at BofA
BofA upgraded AbbVie (ABBV) to Buy from Neutral with a price target of $234, up from $226.
AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?
AbbVie's NYSE: ABBV share price has been under pressure due to rising costs and concerns that its post-Humira days won't be as robust. However, the stock price decline put the market in a position to ...
AbbVie raises FY26 revenue view to about $67.3B from about $67B
FY26 consensus $67.06B.
AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74
Sees Q2 revenue $16.7B, consensus $16.8B.
AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’
09:33 EDT AbbVie (ABBV) sees FY26 adjusted gross margin ‘above 84% of sales’
AbbVie says ‘especially pleased’ with immunology and neuroscience results
Says making “meaningful progress” advancing programs. Says fundamentals of business are “strong.” Comments taken from Q1 earnings conference call.
AbbVie Earnings Call Transcript: Q1 2026
First quarter 2026 results surpassed expectations with 12.4% revenue growth and strong performance in immunology and neuroscience. Full-year guidance was raised, pipeline progress continued, and significant investments in manufacturing and R&D were announced.